JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Catalyst Pharmaceuticals Inc

Fechado

SetorSaúde

20.72 -0.86

Visão Geral

Variação de preço das ações

24h

Atual

Mín

20.66

Máximo

20.94

Indicadores-chave

By Trading Economics

Rendimento

-4.6M

52M

Vendas

5.1M

147M

P/E

Médio do Setor

12.733

37.461

Margem de lucro

35.553

Funcionários

181

EBITDA

5.9M

79M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+57.37% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-79M

2.6B

Abertura anterior

21.58

Fecho anterior

20.72

Sentimento de Notícias

By Acuity

24%

76%

59 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Catalyst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de out. de 2025, 20:49 UTC

Ganhos

Correction to Thermo Fisher Article on Oct. 22

23 de out. de 2025, 23:51 UTC

Conversa de Mercado

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

23 de out. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 de out. de 2025, 23:37 UTC

Conversa de Mercado

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 de out. de 2025, 22:58 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

23 de out. de 2025, 22:57 UTC

Conversa de Mercado

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -2-

23 de out. de 2025, 22:49 UTC

Aquisições, Fusões, Aquisições de Empresas

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 de out. de 2025, 22:17 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 de out. de 2025, 21:41 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 de out. de 2025, 21:05 UTC

Ganhos

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

23 de out. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

23 de out. de 2025, 20:35 UTC

Ganhos

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 de out. de 2025, 20:28 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 de out. de 2025, 20:15 UTC

Conversa de Mercado
Ganhos

Global Commodities Roundup: Market Talk

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Adj EPS $1.71

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q Sales $5.52B

23 de out. de 2025, 20:10 UTC

Ganhos

Newmont Mining 3Q EPS $1.67

23 de out. de 2025, 20:09 UTC

Ganhos

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Global Equities Roundup: Market Talk

23 de out. de 2025, 20:07 UTC

Conversa de Mercado
Ganhos

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 de out. de 2025, 20:07 UTC

Ganhos

Blackstone Looks to IPOs for Investment Exits -- Update

23 de out. de 2025, 20:05 UTC

Ganhos

Intel 3Q Gross Margin 38.2% >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 de out. de 2025, 20:04 UTC

Ganhos

Intel: 4Q Guidance Excludes Altera >INTC

23 de out. de 2025, 20:04 UTC

Ganhos

Intel Sees 4Q Adj EPS 8c >INTC

Comparação entre Pares

Variação de preço

Catalyst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

57.37% parte superior

Previsão para 12 meses

Média 33 USD  57.37%

Máximo 35 USD

Mínimo 31 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Catalyst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

N/A / 24.28Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

59 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
help-icon Live chat